Free IGF-1 Predicts Sensitivity to Figitumumab in NSCLC Patients
Author Information
Author(s): Gualberto A, Hixon M L, Karp D D, Li D, Green S, Dolled-Filhart M, Paz-Ares L G, Novello S, Blakely J, Langer C J, Pollak M N
Primary Institution: The Department of Clinical Development and Medical Affairs, Pfizer Oncology
Hypothesis
Pre-treatment levels of circulating free IGF-1 can predict which NSCLC patients will benefit from figitumumab treatment.
Conclusion
Free IGF-1 may help identify NSCLC patients who benefit from figitumumab therapy.
Supporting Evidence
- Patients with higher free IGF-1 levels had better progression-free survival on figitumumab.
- Free IGF-1 levels correlated with tumor vimentin expression and inversely with E-cadherin.
- High pre-treatment levels of free IGF-1 were predictive of clinical benefit from figitumumab.
Takeaway
Doctors can use a blood test to see if a medicine called figitumumab will help some lung cancer patients.
Methodology
The study tested pre-treatment circulating levels of free IGF-1 in 110 advanced NSCLC patients enrolled in a phase II trial.
Limitations
The study was exploratory and not sufficiently powered for subset safety analysis.
Participant Demographics
68% men, median age 64 years, 49% adenocarcinoma histology, 80% stage IV.
Statistical Information
P-Value
0.005
Confidence Interval
0.22–1.38
Statistical Significance
p=0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website